• Nordic RCC Summit 2023
• Pathology
• Treatment landscape
• First line systemic therapy
• Second line treatment
• Treatment timing, optimization and patient stratification
• AE management
• Quality of Life
• Cabo-nivo combination
• Adjuvant Treatment
• Surgery
• Patient cases

Case experiences with combination therapy with cabozantinib + nivolumab as first-line treatment

Speaker: Interview with Professor Viktor Grünwald.
Date: 2 August 2022
Tags: Cabo-nivo combination, Treatment landscape, First line systemic therapy

Long-Term effectiveness results of CheckMate-9ER

Speaker: Interview with Professor Toni K. Choueiri.
Date: 2 August 2022
Tags: Cabo-nivo combination, Treatment landscape, First line systemic therapy

First-line combination treatments available for renal cell carcinoma

Speaker: Interview with Professor Sumanta Kumar Pal.
Date: 2 August 2022
Tags: Treatment landscape, First line systemic therapy

Nivolumab + Cabozantinib for the treatment of advanced Renal-Cell Carcinoma in 1L

IPSEN and Bristol Myers Squibb webinar.
Speaker: Petri Bono, Viktor Grünwald, MD and Thomas Powles MBBS, MRCP, MD.
Date: 12 October 2021
Tags: Cabo-nivo combination, Treatment landscape, First line systemic therapy

Rationale for combinations with CPI

Speaker: Katarina Puco, Senior Consultant Oncologist. Lovisenberg Diaconal Hospital Norway.
Date: 9 September 2021
Tags: Treatment landscape, First line systemic therapy

Optimal treatment for patients in favorable IMDC risk group

Speaker: Daniel Heinrich and Katriina Jalkanen
Date: 1st December 2023
Tags: Nordic RCC Summit 2023, First line systemic therapy